

SeQuent Scientific Announces 68% growth in EBITDA and 4x jump in PAT for Q2FY19

Mumbai, November 2, 2018: SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the period ended September 30, 2018

Financial Highlights

All values in ₹mn

Particulars	Q2FY19	Q2FY18	Growth (%)	H1FY19	H1FY18	Growth (%)
Revenues	2,517	1,975	27%	4,869	3,918	24.3%
EBITDA	320	190	68%	570	337	68.9%
EBITDA %	12.7%	9.6%	310 bps	11.7%	8.6%	310bps
PAT	155	42	425%	185	35	433%

Commenting on the Q2FY19 results, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: “We delivered robust 27% growth in revenue & 310 basis points margin expansion driven by improved performance across all business verticals. This has resulted in 4 fold increase in profitability for the quarter.

This is the tenth consecutive quarter of consistent growth. We believe this is result of the well defined strategy we set ourselves few years ago and our relentless focus on execution.”

Detailed presentation on the performance forms part of this press release.

Earnings Call with Investors

The Company will conduct an Earnings call at **2:30 PM IST on November 2, 2018** where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

The other numbers are listed in the conference call invite which is posted on the website of the Company.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India’s first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

[sbsubna@christensenir.com](mailto:sbubna@christensenir.com)

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra,
India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Abhishek Singhal

Investor Relations Consultants

abhishek.s@sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.